TMS Coverage for Psychiatric Diagnoses

FDA-Approved Indications

Patients who have failed ECT or other TMS treatments should NOT be excluded from TMS therapy, as this does not disqualify them from coverage or treatment eligibility, according to Molecular Psychiatry 1
TMS is effective in medication-resistant OCD, including studies targeting the supplementary motor area and using various stimulation protocols, as reported by Nature Reviews Disease Primers 2, 3, 4, 5, 6

Two failed adequate antidepressant trials constitute the minimum standard for treatment-resistant depression qualifying for TMS, with each trial at therapeutic dose for at least 4 weeks minimum, as stated by Praxis Medical Insights and Molecular Psychiatry 7, 8, 1
The two failures should involve medications with different mechanisms of action, according to Molecular Psychiatry 8, 1
Discontinuation due to side effects before 4 weeks does NOT count as treatment failure for establishing TRD and TMS eligibility, as noted by Praxis Medical Insights 7

Patients with multiple prior medication failures should NOT be excluded from TMS treatment, even if they have failed numerous augmentation strategies, according to Molecular Psychiatry and Praxis Medical Insights 8, 1, 7
Patients who failed ECT or prior TMS courses should NOT be excluded from subsequent TMS trials, as reported by Molecular Psychiatry 1
Patients with comorbid personality disorders or other mental health conditions can receive TMS unless these conditions clearly preceded and are independent of the MDD diagnosis, according to Molecular Psychiatry 1

Document at least 2 failed adequate antidepressant trials (minimum 4 weeks each at therapeutic dose, different mechanisms of action) to confirm TMS eligibility, as stated by Praxis Medical Insights and Molecular Psychiatry 7, 8
Verify trials occurred within current depressive episode (or within last 2 years for prolonged episodes) to ensure TMS eligibility, according to Praxis Medical Insights 7

Do not deny coverage based solely on high number of prior treatment failures—these patients remain eligible for TMS, as noted by Praxis Medical Insights and Molecular Psychiatry 7, 1
Do not count medication trials discontinued before 4 weeks due to side effects as failed trials for TRD diagnosis, according to Praxis Medical Insights 7
Do not exclude patients who previously failed ECT or TMS—they remain candidates for repeat or alternative TMS protocols, as reported by Molecular Psychiatry 1
Do not require psychotherapy failure as a criterion for TMS eligibility—failed psychotherapy does not count toward TRD definition, according to Molecular Psychiatry 8, 1